Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Private Trust Co. NA

Private Trust Co. NA lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,931 shares of the medical research company’s stock after buying an additional 233 shares during the period. Private Trust Co. NA’s holdings in Edwards Lifesciences were worth $193,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $29,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC increased its stake in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Webster Bank N. A. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $39,000. Finally, Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences in the third quarter worth approximately $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $72.07 on Friday. The firm has a market cap of $42.51 billion, a P/E ratio of 10.40, a P/E/G ratio of 4.01 and a beta of 1.12. The firm has a fifty day moving average of $68.01 and a two-hundred day moving average of $75.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 earnings per share. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $2,657,000 over the last 90 days. 1.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wells Fargo & Company decreased their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Piper Sandler dropped their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Citigroup reduced their price objective on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, Oppenheimer reissued an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average price target of $76.85.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.